Phase 3 Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.600 enrolled2 locationsNCT07118527
Recruiting
Phase 3
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
Phase 2Phase 3
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd.778 enrolled10 locationsNCT06841679
Recruiting
Phase 3
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.450 enrolled22 locationsNCT06238843
Recruiting
Phase 3
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.524 enrolled1 locationNCT06649292